NASDAQ:IMUX

Immunic News Headlines

Top-Rated Stocks  
$12.88
-0.56 (-4.17 %)
(As of 04/20/2021 01:24 PM ET)
Add
Compare
Today's Range
$12.60
Now: $12.88▼
$13.37
50-Day Range
$14.21
MA: $15.34▼
$16.85
52-Week Range
$7.50
Now: $12.88▼
$28.21
Volume3,518 shs
Average Volume226,671 shs
Market Capitalization$272.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21

Headlines

Immunic (NASDAQ IMUX) News Headlines Today

SourceHeadline
Immunics (IMUX) "Buy" Rating Reiterated at WedbushImmunic's (IMUX) "Buy" Rating Reiterated at Wedbush
americanbankingnews.com - April 17 at 3:12 PM
Immunic, Inc. (NASDAQ:IMUX) Short Interest UpdateImmunic, Inc. (NASDAQ:IMUX) Short Interest Update
americanbankingnews.com - April 17 at 9:12 AM
Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.69 Per Share Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.69 Per Share
americanbankingnews.com - April 15 at 2:20 PM
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at AegisImmunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Aegis
americanbankingnews.com - April 15 at 11:56 AM
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose SelectionImmunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
finance.yahoo.com - April 15 at 10:05 AM
Health Care Sector Update for 03/31/2021: IMUX,SURF,CASI,NMTR - NasdaqHealth Care Sector Update for 03/31/2021: IMUX,SURF,CASI,NMTR - Nasdaq
nasdaq.com - March 31 at 8:46 PM
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunics Lead Program, IMU-838Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
markets.businessinsider.com - March 31 at 8:55 AM
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by BrokeragesImmunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - March 31 at 5:00 AM
A myriad of drugs are in the pipeline for Ulcerative Colitis treatment: DelveInsight - GlobeNewswireA myriad of drugs are in the pipeline for Ulcerative Colitis treatment: DelveInsight - GlobeNewswire
globenewswire.com - March 31 at 12:58 AM
Immunic (NASDAQ:IMUX) Earns Market Outperform Rating from Analysts at JMP SecuritiesImmunic (NASDAQ:IMUX) Earns Market Outperform Rating from Analysts at JMP Securities
americanbankingnews.com - March 30 at 8:32 AM
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect - Yahoo FinanceImmunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect - Yahoo Finance
finance.yahoo.com - March 24 at 11:17 PM
Immunic Gets Bullish Rating On Multiple Sclerosis Drug ProspectImmunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
finance.yahoo.com - March 24 at 6:16 PM
Immunic has a potentially good multiple sclerosis candidate: JMP - Seeking AlphaImmunic has a potentially good multiple sclerosis candidate: JMP - Seeking Alpha
seekingalpha.com - March 24 at 1:15 PM
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect - BenzingaImmunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect - Benzinga
benzinga.com - March 24 at 1:15 PM
Should You Take Comfort From Insider Transactions At Immunic, Inc. (NASDAQ:IMUX)?Should You Take Comfort From Insider Transactions At Immunic, Inc. (NASDAQ:IMUX)?
finance.yahoo.com - March 19 at 1:08 PM
Form 10-K IMMUNIC, INC. For: Dec 31 - StreetInsider.comForm 10-K IMMUNIC, INC. For: Dec 31 - StreetInsider.com
streetinsider.com - February 26 at 1:04 PM
Form 8-K IMMUNIC, INC. For: Feb 26 - StreetInsider.comForm 8-K IMMUNIC, INC. For: Feb 26 - StreetInsider.com
streetinsider.com - February 26 at 1:04 PM
Immunics IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study - Yahoo FinanceImmunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study - Yahoo Finance
finance.yahoo.com - February 19 at 2:50 PM
Form 8-K IMMUNIC, INC. For: Feb 17 - StreetInsider.comForm 8-K IMMUNIC, INC. For: Feb 17 - StreetInsider.com
streetinsider.com - February 19 at 9:49 AM
Immunic’s oral immune therapy shows positive effect rare liver disease trial - Seeking AlphaImmunic’s oral immune therapy shows positive effect rare liver disease trial - Seeking Alpha
seekingalpha.com - February 18 at 11:21 PM
Immunics IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease StudyImmunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study
finance.yahoo.com - February 18 at 1:20 PM
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - Yahoo FinanceImmunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - Yahoo Finance
finance.yahoo.com - February 17 at 7:32 PM
Immunic (IMUX) Announces Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - StreetInsider.comImmunic (IMUX) Announces Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial - StreetInsider.com
streetinsider.com - February 17 at 2:31 PM
Immunics IMU-838 shows evidence of clinical activity in COVID-19 - Seeking AlphaImmunic's IMU-838 shows evidence of clinical activity in COVID-19 - Seeking Alpha
seekingalpha.com - February 17 at 2:31 PM
IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks - BenzingaIMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks - Benzinga
benzinga.com - February 17 at 2:31 PM
Immunics IMU-838 Shows Evidence Of Clinical Activity In Moderate COVID-19 In Phase2 Trial - NasdaqImmunic's IMU-838 Shows Evidence Of Clinical Activity In Moderate COVID-19 In Phase2 Trial - Nasdaq
nasdaq.com - February 17 at 2:31 PM
IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock TanksIMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks
finance.yahoo.com - February 17 at 2:30 PM
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 - Yahoo FinanceImmunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 - Yahoo Finance
finance.yahoo.com - February 11 at 7:13 AM
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
finance.yahoo.com - February 11 at 7:13 AM
Immunic: Competitive Phase 2 Data In Multiple Sclerosis - Seeking AlphaImmunic: Competitive Phase 2 Data In Multiple Sclerosis - Seeking Alpha
seekingalpha.com - January 24 at 10:06 AM
Immunic, Inc. to Participate in Investor Conferences in JanuaryImmunic, Inc. to Participate in Investor Conferences in January
finance.yahoo.com - January 5 at 8:50 AM
IDEAYA Biosciences, I-Mab & Immunic will be added to NASDAQ Biotechnology Index - Seeking AlphaIDEAYA Biosciences, I-Mab & Immunic will be added to NASDAQ Biotechnology Index - Seeking Alpha
seekingalpha.com - December 14 at 6:31 PM
Immunic, Inc. to Participate in Investor Conferences in DecemberImmunic, Inc. to Participate in Investor Conferences in December
finance.yahoo.com - November 24 at 9:32 AM
Immunic, Inc. Announces Formation of Scientific-Medical Advisory BoardImmunic, Inc. Announces Formation of Scientific-Medical Advisory Board
finance.yahoo.com - November 17 at 6:53 AM
Form S-3 IMMUNIC, INC. - StreetInsider.comForm S-3 IMMUNIC, INC. - StreetInsider.com
streetinsider.com - November 13 at 10:37 PM
Immunic, Inc. to Participate in Investor and Scientific Conferences in NovemberImmunic, Inc. to Participate in Investor and Scientific Conferences in November
finance.yahoo.com - November 10 at 8:04 AM
Form 10-Q IMMUNIC, INC. For: Sep 30 - StreetInsider.comForm 10-Q IMMUNIC, INC. For: Sep 30 - StreetInsider.com
streetinsider.com - November 6 at 2:58 PM
Immunic: 3Q Earnings Snapshot - Yahoo FinanceImmunic: 3Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - November 6 at 2:58 PM
Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateImmunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 5 at 7:27 PM
Enrollment underway in Immunics Phase 2 part of IMU-838 study in COVID-19Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19
seekingalpha.com - November 2 at 8:49 AM
Immunic Enrolls 200 Patients In Phase 2 CALVID-1 Trial Of IMU-838 - Quick FactsImmunic Enrolls 200 Patients In Phase 2 CALVID-1 Trial Of IMU-838 - Quick Facts
nasdaq.com - November 2 at 8:49 AM
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to ProceedImmunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
finance.yahoo.com - November 2 at 8:48 AM
Coronavirus update: U.S. braces for third wave; Moderna manages vaccine expectationsCoronavirus update: U.S. braces for third wave; Moderna manages vaccine expectations
finance.yahoo.com - October 22 at 12:31 PM
Immunic secures €24.5M in loan financingImmunic secures €24.5M in loan financing
seekingalpha.com - October 22 at 7:30 AM
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy - Yahoo FinanceEIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy - Yahoo Finance
finance.yahoo.com - October 21 at 1:14 AM
EIB Provides Immunic With Up To €24.5M To Support Ongoing Development Of A Potential COVID-19 Therapy - BenzingaEIB Provides Immunic With Up To €24.5M To Support Ongoing Development Of A Potential COVID-19 Therapy - Benzinga
benzinga.com - October 20 at 8:13 PM
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 TherapyEIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
finance.yahoo.com - October 20 at 10:12 AM
Why Immunics Stock Is Trading Higher Today - Yahoo FinanceWhy Immunic's Stock Is Trading Higher Today - Yahoo Finance
finance.yahoo.com - October 2 at 5:42 PM
Cue Biopharma Welcomes Tamar Howson to its Board of Directors - StreetInsider.comCue Biopharma Welcomes Tamar Howson to its Board of Directors - StreetInsider.com
streetinsider.com - September 17 at 10:52 PM
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
finance.yahoo.com - September 11 at 9:12 AM
This page was last updated on 4/20/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.